DaVita HealthCare Partners Upgraded to Outperform at Raymond James (DVA)
DaVita HealthCare Partners (NYSE:DVA) was upgraded by Raymond James from a “market perform” rating to an “outperform” rating in a research note issued on Monday, TheFlyOnTheWall.com reports.
DaVita HealthCare Partners (NYSE:DVA) traded up 0.51% during mid-day trading on Monday, hitting $64.80. 2,101,957 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 52-week low of $52.75 and a 52-week high of $65.665. The stock’s 50-day moving average is $60.61 and its 200-day moving average is $58.32. The company has a market cap of $13.783 billion and a P/E ratio of 23.82.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $3.00 billion for the quarter, compared to the consensus estimate of $2.93 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. The company’s revenue for the quarter was up 54.2% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.81 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at KeyCorp initiated coverage on shares of DaVita HealthCare Partners in a research note to investors on Tuesday, December 17th. They set a “buy” rating on the stock. Separately, analysts at Feltl & Co. raised their price target on shares of DaVita HealthCare Partners from $64.00 to $69.00 in a research note to investors on Tuesday, December 10th. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of DaVita HealthCare Partners from $68.00 to $72.00 in a research note to investors on Monday, November 25th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $100.33.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.